Research Topics
Species | Guy YoungSummaryAffiliation: University of Southern California Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Multifocal Castleman disease in pediatrics: case reportMariana Baserga
Department of Pediatrics, Children's Hospital of Orange County, Orange, CA, USA
J Pediatr Hematol Oncol 27:666-9. 2005..She tolerated her therapy well and is currently free of disease at 36 months of follow-up...- Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formationGuy Young
Department of Hematology, Children s Hospital of Orange County, Orange, California 92868, USA
Blood Coagul Fibrinolysis 18:97-103. 2007..The reduced bleeding reported with DTIs versus heparin may relate to the fact that clots form with normal rigidity and elasticity... 
Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trialGuy Young
Children s Hospital Los Angeles, Los Angeles, California 90027, USA
Blood Coagul Fibrinolysis 19:276-82. 2008..Thus, test conditions may need to be optimized before Thromboelastograph/Rotation Thromboelastography can be utilized for all inhibitor patients...- Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectivesGuy Young
Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA
Blood 121:1944-50. 2013..In this article we review the existing literature and discuss several controversial issues surrounding the assays. Last, a vision of future clinical uses of these assays is briefly described... - New challenges in hemophilia: long-term outcomes and complicationsGuy Young
Hemostasis and Thrombosis Center, Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA
Hematology Am Soc Hematol Educ Program 2012:362-8. 2012..This review discusses some new challenges facing developing nations and their care for hemophilia patients. In summary, in hemophilia in the coming few years, several new challenges will need to be confronted... - Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008)G Young
Children s Center for Cancer and Blood Disorders, Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA
Haemophilia 18:990-6. 2012..Effectiveness of rFVIIa was consistently high across bleeding types and locations... - PRO-PACT: retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitorsGuy Young
Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Thromb Res 130:864-70. 2012..This report describes the clinical experience of secondary prophylaxis in a large population of inhibitor patients... - From boy to man: recommendations for the transition process in haemophiliaGuy Young
Children s Hospital Los Angeles and University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA
Haemophilia 18:27-32. 2012..A well-developed transition plan from birth to adulthood for patients with haemophilia facilitates the necessary change from total dependence on caregivers to complete independence by the time one reaches 18 years of age... - Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE)G Young
Children s Hospital Los Angeles, Los Angeles, CA 90027, USA
Haemophilia 18:392-9. 2012..This suggests that patients/caregivers have adopted home treatment strategies based on physician discretion and individual responses and experience... - Off-label use of rFVIIa in children with excessive bleeding: a consecutive study of 153 off-label uses in 139 childrenGuy Young
Children s Hospital of Orange County, Orange, California, USA
Pediatr Blood Cancer 53:179-83. 2009..Recombinant factor VIIa is a general hemostatic agent. Randomized trials have demonstrated effectiveness in adults; however, data in children are confined to case reports and series subject to publication bias... - Comparison of kaolin and tissue factor activated thromboelastography in haemophiliaG Young
Division of Hematology Oncology, Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA 90027, USA
Haemophilia 16:518-24. 2010..Thus kaolin activated thromboelastography should be considered an effective, perhaps the most effective, activator when utilizing thromboelastography to assess the effects of rFVIIa in haemophilia patients with inhibitors... - Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparisonG Young
Children s Hospital of Orange County, Orange, CA 90027, USA
Haemophilia 14:287-94. 2008..A single dose of rFVIIa 270 microg kg(-1) is as safe and effective as rFVIIa 90 x 3 microg kg(-1) dosing, and may be considered a potentially more effective alternative to APCCs for the management of joint bleeding in this population... - Pilot dose-finding and safety study of bivalirudin in infants <6 months of age with thrombosisG Young
Children s Hospital of Orange County, Los Angeles, CA, USA
J Thromb Haemost 5:1654-9. 2007..Newer anticoagulants have improved properties relative to heparin, and this may enhance the outcome in children... - Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastographyGuy Young
Department of Hematology, Children s Hospital of Orange County, Orange, California, USA
Blood Coagul Fibrinolysis 18:547-53. 2007..In conclusion, rFVIIa effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin, and should be considered for patients with excessive bleeding associated with these anticoagulants... - Transitioning issues in adolescent to young adult hemophilia patients with inhibitors: an approach for a growing populationGuy Young
Hemostasis and Thrombosis Center, Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, California 90027, USA
Blood Coagul Fibrinolysis 21:S7-10. 2010..This review will discuss the various issues ranging from choice of medical provider to a discussion of psychosocial and financial issues facing this specific patient population... - New anticoagulants in children: a review of recent studies and a look to the futureGuy Young
Hemostasis and Thrombosis Center, Children s Hospital Los Angeles, CA, USA
Thromb Res 127:70-4. 2011..Pediatric thrombosis is entering a fruitful era of research in the area of anticoagulation management which is sure to lead to significant changes in how children are treated in the next 10 years... - When should prophylaxis therapy in inhibitor patients be considered?G Young
Children s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
Haemophilia 17:e849-57. 2011..This report will review the current data on prophylaxis with bypassing agents and suggest specific situations in which prophylaxis in inhibitor patients could be considered... - Argatroban therapy in pediatric patients requiring nonheparin anticoagulation: an open-label, safety, efficacy, and pharmacokinetic studyG Young
Division of Hematology Oncology, Children s Hospital Los Angeles, Los Angeles, California, USA
Pediatr Blood Cancer 56:1103-9. 2011..Some such patients develop heparin-induced thrombocytopenia (HIT) and thus require alternative anticoagulation. As such, studies evaluating the safety, efficacy, and dosing of alternative anticoagulants are required... - Old and new antithrombotic drugs in neonates and infantsGuy Young
Hemostasis and Thrombosis Center, Children s Hospital Los Angeles, Los Angeles, CA, USA
Semin Fetal Neonatal Med 16:349-54. 2011..Pediatric thrombosis is entering a fruitful era of research in anticoagulation management, which is sure to lead to significant changes in how children are treated in the next 10 years... - FondaKIDS: a prospective pharmacokinetic and safety study of fondaparinux in children between 1 and 18 years of ageGuy Young
Children s Hospital Los Angeles, University of Southern California, Keck School of Medicine, Los Angeles, California 90027, USA
Pediatr Blood Cancer 57:1049-54. 2011..The incidence of thromboembolic disease is increasing in children. New anticoagulants have been licensed in adults and need to be studied in children. This report describes the first prospective study of fondaparinux in children... - Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiencyAmy E Lovejoy
Department of Hematology, Children's Hospital of Orange County, Orange, CA 92868, USA
Blood 108:57-62. 2006..Recombinant FXIII appears to be a safe and potentially effective alternative for FXIII replacement in patients with FXIII deficiency... - Argatroban as an alternative to heparin in extracorporeal membrane oxygenation circuitsGuy Young
Division of Hematology, Children s Hospital of Orange County, Orange, CA 92868, USA
Perfusion 19:283-8. 2004..These results suggest that argatroban may be more efficacious than heparin for anticoagulation in ECMO. Additional studies are warranted to further evaluate argatroban in this setting... - New approaches in the management of inhibitor patientsGuy Young
Children s Hospital of Orange County, Orange, California 92868, USA
Acta Haematol 115:172-9. 2006..Thus another goal of current research is to develop such a tool which will enable the individualization of bypassing agent... - Recombinant factor VIIa in paediatric bleeding disorders--a 2006 reviewP Mathew
Department of Pediatrics, University of New Mexico, Albuquerque, NM 87131 0001, and Children s Hospital of Orange County, Orange, CA, USA
Haemophilia 12:457-72. 2006..rFVIIa has been administered as both bolus and continuous infusions, and at varying doses. Furthermore, adverse events have not reportedly increased in children despite growing experience with its use in the paediatric population... - Prophylactic recombinant factor VIIa in haemophilia patients with inhibitorsG Young
Department of Pediatric Hematology, Children s Hospital of Orange County, Orange, CA 92868, USA
Haemophilia 11:203-7. 2005..Both patients had an outstanding response to prophylaxis albeit at a very high cost. Prophylaxis with rFVIIa can be an effective approach in select inhibitor patients with severe complications related to bleeding... - Individualization of bypassing agent treatment for haemophilic patients with inhibitors utilizing thromboelastographyG Young
Department of Hematology, Children s Hospital of Orange County, Orange, CA 92868, USA
Haemophilia 12:598-604. 2006..We thus believe that TEG is a promising device for monitoring of bypass agent therapy and should be studied further... - Pharmacokinetic- and pharmacodynamic-based antithrombotic dosing recommendations in childrenRichard Har Ko
Children s Center for Cancer and Blood Diseases, Children s Hospital Los Angeles, Los Angeles, CA 90027, USA
Expert Rev Clin Pharmacol 5:389-96. 2012..The authors reviewed pharmacokinetic and pharmacodynamic studies of anticoagulants in children and make dosing recommendations based on study findings... - Therapy for haemophilia: recent advances and goals for the futureGuy Young
Children s Hospital of Orange County, 455 S Main Street, Orange, CA 92868, USA
Expert Opin Emerg Drugs 10:173-84. 2005..This review will discuss in detail the cu-rrent and future goals of haemophilia therapy... - Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experienceJ Schneiderman
Department of Pediatric Hematology, Children s Hospital of Orange County, Orange, CA, USA
Haemophilia 13:244-8. 2007..Thromboelastography demonstrated an additive effect. Sequential therapy is a safe, potentially efficacious approach in the management of refractory bleeding episodes in patients with haemophilia and inhibitors... - Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitorsJ Schneiderman
Department of Pediatric Hematology, Children's Hospital of Orange County, 455 S. Main Street, Orange, CA 92868, USA
Haemophilia 10:347-51. 2004.... - Bleeding symptoms and laboratory correlation in patients with severe von Willebrand diseaseA D Metjian
Penn Comprehensive Hemophilia and Thrombosis Program, Division of Hematology Oncology, University of Pennsylvania, Philadelphia, PA 19104, USA
Haemophilia 15:918-25. 2009..This study documents the strong bleeding phenotype in severe VWD and provides data to help target therapy, including prophylaxis, for patients most at risk of bleeding complications... - Current and future antithrombotic agents in childrenGuy Young
Children s Hospital of Orange County, 455 S Main Street, Orange, CA 92868, USA
Expert Rev Cardiovasc Ther 2:523-34. 2004..This review will discuss the currently available agents, with an emphasis on those that are novel and their potential uses in children... - Pediatric stroke and methylenetetrahydrofolate reductase polymorphisms: an examination of C677T and A1298C mutationsJames L Rook
Children s Hospital of Orange County, Orange, CA 92868, USA
J Pediatr Hematol Oncol 27:590-3. 2005..The results of our study suggest that mutations in MTHFR are associated with pediatric stroke. However, additional studies are required to confirm our findings and to determine if this relationship is causal... - Diagnosis and treatment of thrombosis in children: general principlesGuy Young
Children s Hospital of Orange County, Mattel Children s Hospital at UCLA, Orange, California 92868, USA
Pediatr Blood Cancer 46:540-6. 2006..In the near future, the results of these studies will allow for better management of pediatric patients with thrombosis... - Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in childrenMichael D Tarantino
Comprehensive Bleeding Disorders Center, University of Illinois College of Medicine, Peoria, Illinois 61614, and Children s Hospital of Orange County, Orange, California, USA
J Pediatr 148:489-94. 2006.... - Rofecoxib as adjunctive therapy for haemophilic arthropathyB Rattray
Division of Hematology, Children's Hospital of Orange County, Orange, CA 92868, USA
Haemophilia 11:240-4. 2005..This is the largest study to date evaluating COX-2 inhibitors as adjunctive therapy in haemophilia and suggests that these agents may be an important adjunctive therapy in the management of haemophilia... - Celecoxib in the treatment of haemophilic synovitis, target joints, and pain in adults and children with haemophiliaB Rattray
Division of Hematology, Children's Hospital of Orange County, Orange, CA 92868, USA
Haemophilia 12:514-7. 2006..This is the first study evaluating celecoxib as adjunctive therapy in haemophilia and suggests that celecoxib is safe and effective in treating chronic synovitis and joint pain similar to the previous study of rofecoxib... - Current therapy for rare factor deficienciesJ Di Paola
Division of Hematology, Children's Hospital of Orange County, Orange, California 92868, USA
Haemophilia 7:16-22. 2001..In addition, recombinant factor VIIa is available for treating factor VII deficient patients... - Long-term treatment of refractory thrombocytopenia in a patient with Wiskott-Aldrich syndrome with vincristine, immunoglobulin, and methylprednisoloneG Young
Department of Pediatrics, Division of Hematology Oncology, Loma Linda University, Loma Linda, California 92350, USA
Am J Hematol 62:183-5. 1999..Our patient had a sustained remission of symptomatic thrombocytopenia without toxicity. Furthermore, pulse dexamethasone might be an alternative treatment option to which patients with Wiskott-Aldrich syndrome may respond... - Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium studyG Young
Children s Hospital of Orange County, Orange, California 92868, USA
J Thromb Haemost 1:958-62. 2003..Therefore, children with arterial or venous thrombosis of any location should be evaluated for the presence of the prothrombin mutation... - Heparin use in childrenGuy Young
Pediatr Res 61:139-40. 2007
Research Grants
- FONDAPARINUM IN CHILDREN WITH THROMBOSISGuy Young; Fiscal Year: 2007..Pharmacokinetic analyses as well as safety and efficacy determinations will be made which will provide valuable information on this new anticoagulant for pediatric patients. ..
- Dose-finding, pharmacokinetic, safety and efficacy of bivalirudin in childrenGuy Young; Fiscal Year: 2009..More modern therapies are available but have not been systematically tested in children. This study will determine whether one such medication, bivalirudin is a safer and more effective alterative. ..